Abstract Article


Nutraceuticals in the management of alzheimer’s disease

Meraj Khan*, Seerat Anwar

ONLINE ISSN : 2456-8244



The aim of this review is attempts to enlist and display the role of some nutraceuticals being used as in the prevention and management of Alzheimer's disease. Various cognitive enhancer are widely used traditionally as medicine to prevent Alzheimer's disease. Nutraceuticals are food or part of a food including naturals (like plants, animals, minerals, or microbial sources) or chemical groups (like vitamins, antioxidants, amino acids and fatty acids) that promote wellness or health benefits including the prevention and/or treatment of a disease. One of the best benefits of nutraceuticals is that they provide a better therapeutic hope with lesser side effects compared to pharmaceutical agents or other conventional approach. Some of the herbal nutraceuticals like Gingko Biloba, Huperzine Alpha are used in clinical practice to target the pathogenesis of Alzheimer's disease.


Nutraceuticals, Alzheimer's disease, Herbal Drugs, Gingko Biloba, Huperzine Alpha, Vitamins.



1. Goodman Gilman A, Goodman LS, Rall TW, Murad F Eds. Goodman & Gilman's The Pharmacological Basis Of Therapeutics. New York: Macmillan Publishing Company, 7th ed. 1985; pp 560-62 2. Dementia Fact Sheet, World Health Organisation. 2016 3. Levine DA, Langa KM. Vascular cognitive impairment: disease mechanisms and therapeutic implications. Neurotherapeutics 2011; 8(3): 361–373 4. Skoog I. Status of risk factors for vascular dementia. Neuroepidemiology 1998; 17(1): 2–9 5. Tiraboschi P, Hansen LA, Thal LJ, Corey- Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 2004; 62(11): 1984-1989 6. Wright CI, Geula C, Mesulam MM: Neurological cholinesterase in the normal brain and in Alzheimer's disease: Relation to plaques, tangles, and patterns of selective vulnerability. Annals of Neurology 1993; 34: 373-384. 7. Francis PT, Palmer AM, Snape M, et al.,The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol ,neurosurg Psychiatry 1999; 54: 137-147. 8. Brower V. Nutraceuticals: Poised for a healthy slice of the healthcare market? Nature Biotechnology 1998; 16: 728-731 9. Smith JV, Luo Y. Studies on molecular mechanisms of Ginkgo biloba extract. Applied Microbiology and Biotechnology 2004; 64(4): 465–472 10. http://www.herbal-supplement-resource.com 11. http://www.richters.com 12. Maurer K, Ihl R, Dierks T, Frolich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. Journal of Psychiatric Research 1997; 31(6): 645–655 13. Mazza M, Capuano A, Bria P, Mazza S. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer‟s dementia in a randomized placebo-controlled double-blind study. European Journal of Neurology 2006; 13(9): 981– 985 14. Wang R, Xi CT. Neuroprotective effects of huperzine A: a natural cholinesterase inhibitor for the treatment of Alzheimer‟s disease. NeuroSignals 2005; 14(1-2): 71-82 15. http://www.holistictherapypractice.com 16. Zhang Z, Wang X, Chen Q, Shu L, Wang J, Shan G. Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo- controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi 2002; 82: 941-944 17. Xu SS, Cai ZY, Qu ZW, Yang RM, Cai YL, Wang GQ, Su XQ, Zhong XS, Cheng RY, Xu WA, et al. Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Zhongguo Yao Li Xue Bao 1999; 20: 486-490. 18. Perry EK, Pikering AT, Wang WW, et al.: Medicinal plants and Alzheimer's disease: Integrating ethnobotanical and contemporary scientific evidence. Journal of Alternate and Complementary Medicine 1998; 4: 419-428. 19. Kennedy DO, Scholey AB, Tildesley NTJ, et al.: Modulation of mood and cognitive performance following acute administration of Melissa officinalis lemon balm. Pharmacol ogy Biochemisty and Behavior 2002; 72: 953- 964. 20. Akhondzadeh S, Noroozian M, Mohammadi M, et al.: Melissa officinalis extract in the treatment ofpatients with mild to moderate Alzheimer's disease: A double blind, randomised, placebo controlled trial. Journal of Neurology, Neurosurgery and Psychiatry 2003; 74: 863-866. 21. Wake G, Court J, Pikering A, et al.: CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. Journal of Ethnopharmacology 2000; 69: 105-114. 22. Akhondzadeh S, Noroozian M, Mohammadi M, et al.: Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double blind, randomized and placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics 2003; 28: 53-59. 23. Russo A, Borrelli F. Bacopa monniera, a reputed nootropic plant: an overview. Phyto medicine 2005; 12(4): 305-317 24. Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S. Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Phytotherapy Research 2000; 14(3): 174–179 25. Russo A, Izzo AA, Borrelli F, Renis M, Vanella A. Free radicalbscavenging capacity and protective effect of Bacopa monniera L. on DNA damage. Phytotherapy Research 2003; 17(8): 870-875 26. Kamkaew N, Scholfield CN, Ingkaninan K, N. Taepavarapruk N, Chootip K. Bacopa monnieri increases cerebral blood flow in rat independent of blood pressure. Phytotherapy Research 2013; 27(1): 135-138 27. Kar Chowdhuri D, Parmar D, Kakkar P, Shukla R, Seth PK, Srimal RC. Antistress effects of bacosides of Bacopa monnieri modulation of Hsp70 expression, superoxide dismutase and cytochrome P450 activity in rat brain. Phytotherapy Research 2002; 16(7): 639-645 28. Kishore K, Singh M. Effect of bacosides, alcoholic extract of Bacopa monniera Linn.(brahmi) on experimental amnesia in mice. Indian Journal of Experimental Biology 2005; 43(7): 640-645 29. Goswami S, Saoji A, Kumar N, Thawani V, Tiwari M, Thawani M. Effect of Bacopa monnieri on Cognitive functions in Alzheimer‟s disease patients. International Journal of Collaborative Research in Internal Medicine and Public Health 2011; 3: 285-293. 30. http://www.alz.org/research/science/alzhei mers treatment horizon.asp 31. http://www.alz.org/research/clinical trials/find clinical trials trialmatch.aspf